Standard BioTools Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $85.3M | $91.0M | $106.3M | $97.9M | $130.6M | $138.1M | $117.2M |
| Cost of Revenue | — | $42.8M | $46.1M | $55.9M | $60.9M | — | — | $53.0M |
| Gross Profit | — | $42.5M | $44.9M | $50.5M | $37.1M | — | — | $64.3M |
| Gross Margin | — | 49.9% | 49.3% | 47.4% | 37.8% | — | — | 54.8% |
| Operating Expenses | ||||||||
| Research & Development | — | $26.0M | $28.8M | $25.9M | $37.4M | $37.9M | $36.5M | $31.6M |
| SG&A Expense | — | $109.9M | $103.1M | $87.5M | $102.3M | $98.9M | $97.9M | $84.5M |
| Operating Income | — | $-110.2M | $-127.5M | $-76.6M | $-116.2M | $-67.5M | $-51.0M | $-51.8M |
| Operating Margin | — | -129.2% | -140.1% | -72.0% | -118.6% | -51.7% | -36.9% | -44.2% |
| Interest Expense | — | — | — | $4.6M | $4.3M | $3.8M | $3.6M | $4.3M |
| Pretax Income | — | $-96.7M | $-90.4M | $-74.2M | $-192.9M | $-63.7M | $-54.1M | $-66.7M |
| Income Tax Expense | — | $-37.9M | $542.0K | $452.0K | $-2.8M | $-4.4M | $-1.1M | $-1.9M |
| Net Income | — | $-74.9M | $-138.9M | $-74.7M | $-190.1M | $-59.2M | $-53.0M | $-64.8M |
| Net Margin | — | -87.8% | -152.6% | -70.2% | -194.1% | -45.4% | -38.4% | -55.3% |
| EPS (Basic) | — | $-0.20 | $-0.52 | $-0.24 | $-0.61 | $-0.20 | $-0.19 | $-0.24 |
| EPS (Diluted) | — | $-0.20 | $-0.52 | $-0.24 | $-0.61 | $-0.20 | $-0.19 | $-0.24 |
| Shares Outstanding (Basic) | 390.1M | 381.6M | 353.2M | 316.6M | 313.2M | 303.1M | 288.2M | 267.1M |
| Shares Outstanding (Diluted) | 390.1M | 381.6M | 353.2M | 316.6M | 313.2M | 303.1M | 288.2M | 267.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |